Hepatitis C antibody test obtains CE mark

It has been estimated that 3 to 4 million people are infected with hepatitis C virus (HCV) each year with the risk of developing liver cirrhosis and/or liver cancer. More than 350,000 people die each year from HCV-related conditions. With earlier detection and diagnosis, patients have a hope of receiving timely treatment and care for improved management of the condition. MP Biomedicals recently obtained the CE Marking for its patented multiparameter HCV test, the Multisure HCV antibody test. This test is intended for the detection and differentiation of Hepatitis C antibodies that may be present in patients with acute or chronic HCV infection. This innovative test is based on the patented reverse-flow technology, giving greater sensitivity and stronger visual signals. Multisure HCV uses human whole blood, plasma or serum. The test is fast and can help differentiate HCV antibodies against both structural and non-structural proteins across six genotypes.

www.mpbio.com